Nova Publishers
My Account Nova Publishers Shopping Cart
HomeBooksSeriesJournalsReference CollectionseBooksInformationSalesImprintsFor Authors
            
  Top » Catalog » Books » Most recent entries » Horizons in World Cardiovascular Research. Volume 2 Chapters » My Account  |  Cart Contents  |  Checkout   
Quick Find
  
Use keywords to find the product you are looking for.
Advanced Search
What's New? more
Counterfeit Parts in the Department of Defense Supply Chain: Reporting Challenges and Risk Issues
$55.80
Shopping Cart more
0 items
Information
Shipping & Returns
Privacy Notice
Conditions of Use
Contact Us
Notifications more
NotificationsNotify me of updates to Beneficial Clinical Effects of Perhexiline in Cardiac Patients: Multiple Biochemical Mechanisms, pp. 1-27
Tell A Friend
 
Tell someone you know about this product.
Beneficial Clinical Effects of Perhexiline in Cardiac Patients: Multiple Biochemical Mechanisms, pp. 1-27 $100.00
Authors:  (Yuliy Y. Chirkov, Aaron L. Sverdlov, John D. Horowitz, Basil Hetzel Institute, The Queen Elizabeth Hospital/Dept. of Medicine, The University of Adelaide, Australia)
Abstract:
Perhexiline, 2-(2,2-dicyclohexylethyl)piperidine, was originally developed as a prophylactic anti-anginal drug in the late 1960s. It was initially a popular and effective treatment for angina, having the almost unique property compared to other agents available at that time, of not inducing reductions in blood pressure or heart rate. Despite the initial success, its use diminished markedly due to the occurrence during long-term therapy of poorly understood side effects (neurotoxicity and hepatotoxicity), which later were shown to be associated with high plasma concentrations of perhexiline, occurring in patients with relatively slow hepatic metabolism of the drug. However, therapeutic plasma monitoring and associated dose adjustments have led to perhexiline's reintroduction into clinical practice. Recent clinical data have proved its safety and
maintained efficacy. Perhexiline reduced anginal frequency in patients with refractory angina. In patients with chronic heart failure, perhexiline improved peak exercise oxygen consumption, left ventricular ejection fraction, symptoms, resting and peak stress
myocardial function. Perhexiline also appears to be effective in suppressing symptoms in patients with acute coronary syndromes or with advanced and inoperable aortic valvular stenosis. Herein we discuss perhexiline's pharmacology with particular emphasis on its
mechanism(s) of action. 


Available Options:
Version:
Special Focus Titles
01.Public Health: International Aspects on Environment and Health
02.Ageing and Mental Health: Global Perspectives
03.Alpha-Fetoprotein: Functions and Clinical Applications
04.Alternative Medicine: Perceptions, Uses and Benefits and Clinical Implications
05.Aluminum Neurotoxicity: From Subtle Molecular Lesions to Neurological Diseases
06.Accessing Justice through Mental Health Law Reform in the Pacific
07.The Fifty Most Influential Americans: Interviews with Professor Donald Elder III
08.Designing Optimal Models of Financial Regulation in a Changing Financial Environment
09.Growing Up in the Middle East: The Daily Lives and Well-Being of Israeli and Palestinian Youth
10.Praxeological Learning: Service-Learning in Teacher Education
11.Case Applications of Statistical Models in Ecology and Evolution
12.Psychology of Creativity: Cognitive, Emotional, and Social Processes

Nova Science Publishers
© Copyright 2004 - 2016

Beneficial Clinical Effects of Perhexiline in Cardiac Patients: Multiple Biochemical Mechanisms, pp. 1-27